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FRS and CACS (C-statistic: 0.75 vs. 0.70, P-value = 0.015). Likewise, the addition of CCTA improved
category-free net reclassification (cNRI) of MACE in patients within the highest age tertile (e.g. cNRI
= 0.75; proportion of events/non-events reclassified were 50 and 25%, respectively; P-value <0.05, all).
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the prediction of MACE in asymptomatic older adults.
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Aims Coronary computed tomography angiography (CCTA) and coronary artery calcium score (CACS) have prognostic value
for coronary artery disease (CAD) events beyond traditional risk assessment. Age is a risk factor with very high weight
and little is known regarding the incremental value of CCTA over CAC for predicting cardiac events in older adults.
...................................................................................................................................................................................................
Methods
and results
Of 27 125 individuals undergoing CCTA, a total of 3145 asymptomatic adults were identified. This study sample was
categorized according to tertiles of age (cut-off points: 52 and 62 years). CAD severity was classified as 0, 1–49,
and >_50% maximal stenosis in CCTA, and further categorized according to number of vessels >_50% stenosis. The
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Framingham 10-year risk score (FRS) and CACS were employed as major covariates. Major adverse cardiovascular
events (MACE) were defined as a composite of all-cause death or non-fatal MI. During a median follow-up of
26 months (interquartile range: 18–41 months), 59 (1.9%) MACE occurred. For patients in the top age tertile, CCTA
improved discrimination beyond a model included FRS and CACS (C-statistic: 0.75 vs. 0.70, P-value = 0.015). Likewise,
the addition of CCTA improved category-free net reclassification (cNRI) of MACE in patients within the highest age
tertile (e.g. cNRI = 0.75; proportion of events/non-events reclassified were 50 and 25%, respectively; P-value <0.05, all).
CCTA displayed no incremental benefit beyond FRS and CACS for prediction of MACE in the lower age tertiles.
...................................................................................................................................................................................................
Conclusion CCTA provides added prognostic value beyond cardiac risk factors and CACS for the prediction of MACE in
asymptomatic older adults.
                                                                                                                                                                                                                   
Keywords elderly • risk assessment • coronary computed tomography angiography • coronary artery calcium score
Introduction
In recent years, risk assessment of coronary artery disease (CAD)
based on traditional risk factors such as Framingham 10-year risk score
(FRS) has been widely used.1,2 However, previous studies have docu-
mented that these risk prediction tools display limited predictive value
in asymptomatic populations within a primary prevention setting.3,4 To
this end, much effort has focused on improving CAD risk prediction,
particularly by employing more novel non-invasive imaging modalities
such as the coronary artery calcium score (CACS).
Coronary computed tomography angiography (CCTA) has
emerged as a highly useful non-invasive diagnostic tool for the diagno-
sis of CAD since it permits reliable visualization of the coronary
arteries and identification of coronary artery stenosis.5–7 Even though
it has clearly been demonstrated that coronary atherosclerosis
shown by contrast-enhanced CCTA has predictive value regarding
future cardiovascular disease events, several studies and analyses
have shown no or very limited incremental value of CCTA beyond
CACS in the general asymptomatic population.8,9 However, there
was a demonstrable incremental value of CCTA for risk stratification
beyond CACS in some high-risk populations, for example in patients
with diabetes, high clinical risk score, or high calcium score.10–12
Advanced age is a strong risk factor for CAD development and its
progression, and is closely associated with future adverse CAD out-
comes.13 Little is known about the incremental benefit of CCTA for
predicting adverse cardiac events beyond CACS in older adults. This
study sought to evaluate the incremental value of CCTA beyond
traditional cardiac risk factors and CACS in a sample of asymptomatic
adults stratified by age.
Methods
Study population
The Coronary CT Angiography Evaluation for Clinical Outcomes: An
International Multicenter (CONFIRM) registry is a dynamic, international,
multicentre, observational cohort study designed to evaluate the associ-
ation between patient characteristics, CCTA findings and adverse clinical
events. In total, 27 125 consecutive patients underwent CCTA at 12 cen-
tres in 6 countries (USA, Canada, Germany, Italy, Switzerland, and South
Korea) between 2005 and 2009. Details of the rationale and design of the
CONFIRM registry have been described previously.14 Various sub-
studies have been published or submitted from the CONFIRM registry
(see Supplementary data online, Table S1). For the purpose of this study,
we excluded individuals who had previous chest pain or shortness of
breath (n= 21 267), a prior history of obstructive CAD, coronary revas-
cularization, myocardial infarction, or coronary artery bypass surgery
(n= 494). We further excluded patients with an absence of concurrent
CACS (n= 1424), lack of available follow-up data for all-cause mortality
and non-fatal myocardial infarction (n= 718), or missing risk factor infor-
mation that would preclude calculating the FRS (n= 77). Hence, a total
3175 patients remained for the current analysis (Figure 1). The study
population was stratified into tertiles based on age and defined as: young
(age < 52 years), intermediate (age 52–62 years), or old age (age > 62 -
years). Indications for performing CCTA in asymptomatic individuals
were the assessment of CAD in patients with previous history of periph-
eral artery disease and/or cerebrovascular disease, pre-operational evalu-
ation, pre-procedural assessment for electrophysiological procedure or
congenital heart disease. However, site-initiated clinical indications were
unavailable for review. The appropriate institutional review board com-
mittees approved the study protocol for all centres and informed consent
was provided by all of the study participants.
DATA and image acquisition
CCTA was performed with site-specific protocols using multi-detector
CT scanners with more than 64 detector rows and following Society of
Figure 1 Study flow chart. CAD, coronary artery disease; PCI,
percutaneous coronary intervention; CABG, coronary artery by-
pass graft; CACS, coronary artery calcium score; FRS, Framingham
10-year risk score.
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..Cardiovascular Computed Tomography (SCCT) guidelines.15 CACS
was calculated according to the methods described by Agatston
et al.16 CCTA data were interpreted on-site using multi-planar recon-
struction and maximum intensity projections. Results were docu-
mented per coronary segment based on a 16-segment modified SCCT
coronary artery model. In each coronary segment, coronary athero-
sclerosis was defined as any tissue structure >1 mm2 either within the
coronary artery lumen or adjacent to the coronary artery lumen that
could be discriminated from surrounding pericardial tissue, epicardial
fat, and the vessel lumen itself. The severity of obstructive CAD was
defined as no CAD (0%), non-obstructive CAD (1–49%), or obstruct-
ive CAD (>_50%), and was further categorized according to the num-
ber of major epicardial vessels with the presence of >_50% stenosis.
Presence of >_50% stenosis in the left main coronary artery was con-
sidered as a 3-vessel disease equivalent.
Study endpoint
Participants were followed for major adverse cardiovascular events
(MACE), with MACE was defined as all-cause mortality and non-fatal MI.
In this study, MI was defined according to the Universal Definition of
Myocardial Infarction.17 The study procedures for follow-up have been
previously described in detail.14 Briefly, ascertainment of death and MI
events were determined by direct/telephone interview, as well as review
of medical charts, and/or query of the national medical database at each
institution by a dedicated physician and/or research nurse.
Statistical methods
Continuous variables are expressed as mean ± standard deviation (SD),
and categorical variables are reported as counts with proportions.
Comparisons between age tertiles were performed by use of a one-way
analysis of variance for continuous variables (ANOVA) and by Pearson’s
v2 test for categorical measures. The FRS was calculated using a trad-
itional risk stratification algorithm as described elsewhere,2 and
participants were assigned to either low (<10%), intermediate (10–20%),
or high (>20%) risk groups. For CACS, participants were categorized
based on the following scores: 0–10, 11–100, and >100. The incidence of
MACE (events per 1000 person-years at risk) was calculated to deter-
mine the risk of MACE across age tertiles. Cox proportional hazards re-
gression was performed to test the interaction between older age and
stenosis severity in CCTA on MACE. When assessing the incremental
prognostic value of CCTA over risk factors and CACS, we employed the
following models: FRS alone, FRSþCACS, and FRSþCACSþCCTA
stenosis severity. Harrell’s C-index was used to assess discrimination of
MACE events for each model and C-indexes were compared using the
method described by DeLong et al.18 Category-free net reclassification
improvement (cNRI) was used to estimate reclassification performance
of each model. In addition, we performed cNRI to account for CCTA
over CAC after stratified by FRS categories. All statistical analyses were
performed using SAS (version 9. 3; SAS Institute, Cary, NC, USA) and
STATA (version 14; StataCorp, College Station, TX, USA), and a P-value
<0.05 was considered statistically significant.
Results
Baseline characteristics
The mean age in the 3175 patients was 56.6 ± 11.3 years and 62.7%
were male. Tertiles of age were 18–51 years (young), 52–62 years
(intermediate), and 63–92 years (elderly) (Table 1). The prevalence of
hypertension, diabetes, and dyslipidaemia tended to rise with increas-
ing age. Conversely, the proportion of male gender, current smoking
status, and family history of CAD declined with advancing age. High
CACS categories were more prevalent within the older age tertile.
Likewise, the percentage of patients in higher FRS categories signifi-
cantly increased with advancing age (see Table 1).
............................................................................................................
....................................................................................................................................................................................................................
Table 1 Baseline characteristics according to age tertiles
Overall Age tertiles P-value
First (n5 990) Second (n5 1090) Third (n5 1065)
Age (years) 56.6 ± 11.3 43.8 ± 6.6 56.4 ± 2.9 68.6 ± 5.4 <0.001
Gender (male) 1973 (62.7) 701 (70.8) 678 (62.2) 594 (55.8) <0.001
BMI 26.7 ± 4.5 26.8 ± 4.6 26.9 ± 4.8 26.3 ± 4.0 <0.001
Hypertension 1439 (46.3) 335 (34.2) 505 (46.9) 599 (57.1) <0.001
Diabetes 392 (12.5) 76 (7.7) 132 (12.1) 184 (17.3) <0.001
Dyslipidaemia 1732 (55.5) 428 (43.5) 658 (60.8) 646 (61.4) <0.001
Current smoking 405 (12.9) 169 (17.1) 140 (12.8) 96 (9.0) <0.001
Fhx of CAD 789 (25.7) 303 (31.3) 283 (26.5) 203 (19.5) <0.001
CACS category <0.001
0–10 1873 (59.6) 766 (77.4) 644 (59.1) 463 (43.5)
10–100 575 (18.3) 119 (12.0) 220 (20.2) 236 (22.2)
101–400 420 (13.4) 75 (7.6) 145 (13.3) 200 (18.8)
>400 277 (8.8) 30 (3.0) 81 (7.4) 166 (16.6)
FRS category <0.001
Low (<10) 1687 (53.6) 853 (84.2) 505 (46.3) 329 (30.9)
Intermediate (10–20) 993 (31.6) 118 (11.9) 457 (41.9) 418 (39.3)
High (>20) 465 (14.8) 19 (1.9) 128 (11.7) 318 (29.9)
BMI, body mass index; CAD, coronary artery disease; CACS, coronary artery calcium score; FRS, Framingham 10 year risk score.
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Prevalence and severity of CAD in CCTA
The prevalence of any CAD was 27.2% for the first tertile, and
increased monotonically for the second (51.9%), and third (67.9%)
tertiles, respectively (P-value for v2 < 0.001, Figure 2). Similarly, the
percentage reflecting the number of vessels with coronary stenosis
was considerably higher for the highest age tertile (P-value <0.001,
for all).
MACE during study follow-up
During a median 26 (interquartile range: 18–41) months of study fol-
low-up, a total of 59 (1.9%) MACE events (e.g. 44 deaths and 15 MIs)
occurred. Foremost, the incidence of MACE was 4.4 [95% confi-
dence interval (95% CI): 2.4–8.3] and 4.9 (95% CI: 2.8–8.4) events
per 1000 person-years for the first and second tertiles, respectively,
increasing further to 13.9 (95% CI: 10.1–19.3) events per 1000 per-
son years among those belonging to the third tertile (Table 2).
Prognostic value of CCTA beyond CACS
and FRS
As expected, in the overall study population, CACS displayed further
incremental benefit over the FRS model for predicting MACE (e.g.
C-statistic for FRS = 0.63; 95% CI, 0.55–0.71 vs. FRSþCACS = 0.71;
95% CI, 0.64–0.78, P for difference = 0.022, Table 3). In similar fashion,
CCTA stenosis significantly increased the C-statistic when added to
the FRS model (Table 3). Although, in the overall population, there
appeared to be no further incremental value when CCTA was added
to the FRS model that also contained CACS. The results of the inter-
action test between older age group and CCTA stenosis for MACE
showed significant result (P-value 0.005).
Notably, the addition of CCTA stenosis improved discrimination
beyond FRS and CACS only for those belonging to the highest (third)
age tertile (e.g. C-statistic for FRSþCACS = 0.70; 95% CI, 0.47–0.68
vs. FRSþCACSþCCTA stenosis = 0.75; 95% CI, 0.68–0.83, P for
difference = 0.015, Table 3). In contrast, CCTA displayed no incre-
mental benefit over FRS and CACS for discrimination of MACE
amongst the lower age tertiles. For those in the uppermost age
tertile, CCTA stenosis led to improved reclassification of MACE
when added to FRS and CACS (Table 4). That is, the addition of
CCTA to the FRSþCACS model correctly improved reclassification
of events (cNRI = 50%) and non-events (cNRI = 25%) for those be-
longing to the third age tertile (P-value <0.05, for both).
Reclassification of elderly population by
CCTA over CACS and FRS
In the uppermost age tertile, 10 MACE events (2.1%) occurred
among 466 patients with 0–10 CACS (Table 5). Seven patients have
non-obstructive CAD or obstructive CAD by CCTA, though CACS
classified these participants as low risk category (CACS 0–10).
Conversely, 101 (65.6%) patients with CACS > 400 have obstructive
CAD by CCTA. In those patients with high CACS, the prevalence of
MACE is significantly lower in patients with no or non-obstructive
CAD (3%, 2/65) compared with patients with obstructive CAD
(11.8%, 12/101).
When we further stratified by FRS categories for participants in
the uppermost age tertile, the improvement of reclassification of
CCTA over CAC was particularly significant among patients with
intermediate and high FRS (45.2% in intermediated FRS and 67.6% in
high FRS, P-value <0.05 for both) (Table 5). Notably, participants with
CACS 0–10 and 10–100 did not experience MACE event in low FRS
group.
Discussion
In this prospective observational multicentre registry, CCTA im-
proved risk prediction above and beyond FRS and CACS among
older aged adults. In particular, CCTA improved reclassification of
elderly patients with and without MACE when added to a prediction
model that comprised FRS and CACS. However, no further benefit
of CCTA was observed in younger and middle aged adults. These re-
sults are fitting with prior studies that documented that CCTA pro-
vides added benefit beyond CACS in selected subgroups of
asymptomatic high-risk patients.10–12,19
Previous studies have reported that CCTA might prove useful for
identifying subclinical CAD in certain asymptomatic populations.20,21
Our group previously explored the predictive value of traditional risk
factors, CACS, and CCTA for future CAD events in 7590
Figure 2 Prevalence of CAD by tertiles of age (P-value <0.001,
for all). CAD, coronary artery disease; VD, vessel disease; LM, left
main coronary artery.
.................................................................................................
Table 2 Major adverse cardiovascular events accord-
ing to age tertiles
Number of
patients
Number of
MACE
(Deaths)
Incident MACE per
1000 person-years
Overall 3145 59 (44) 7.9 (6.1–10.1)
Age tertiles
First 990 10 (7) 4.4 (2.4–8.3)
Second 1090 13 (9) 4.9 (2.8–8.4)
Third 1065 36 (28) 13.9 (10.1–19.3)
MACE, major adverse cardiovascular event; MACE was defined as a composite of
death or MI.
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..asymptomatic patients from the CONFRIM registry.8 On the back-
ground of those findings, although CCTA and CACS individually im-
proved performance over the base model (e.g. FRS and traditional
CAD risk factors), the addition of CCTA beyond a model that con-
tained CACS failed to provide a clinically meaningful benefit. Despite
this, few prior studies have reported an improved prognostic benefit
of CCTA over CACS in asymptomatic individuals who presented
with high risk of CAD. In another study utilizing the same cohort of
the current study, CCTA findings improved risk stratification over
and above CACS in asymptomatic diabetic patients, thus demonstrat-
ing the incremental benefit of CCTA beyond CACS in selected popu-
lations (Min et al.10). Not only from CONFIRM registry, Plank et al.11
revealed that CCTA parameters, especially non-calcified plaque bur-
den, afforded additional prognostic value over CACS in 711 asymp-
tomatic patients with high risk of CAD based on clinical risk factors.10
However, few studies have established whether the incremental
............................................................................. .............................................................................
....................................................................................................................................................................................................................
Table 4 Performance of coronary computed tomography angiography for reclassifying major adverse cardiovascular
events
Model Versus FRS Versus FRS1CACS
cNRI 95% CI % Events
reclassified
% Non-events
reclassified
cNRI 95% CI % Events
reclassified
% Non-events
reclassified
Overall
FRSþCACS 0.52* 0.26–0.77 -5 57*
FRSþCACSþCCTA stenosis 0.49* 0.23–0.74 12 37* 0.47* 0.22–0.73 8 39*
First Tertile
FRSþCACS -0.01 -0.39–0.36 -80* 79*
FRSþCACSþCCTA stenosis 0.22 -0.35–0.79 -40 62* -0.04 -0.53–0.46 -60 57*
Second Tertile
FRSþCACS 0.52 -0.03–1.06 -8 59*
FRSþCACSþCCTA stenosis -0.06 -0.57–0.44 -38 32* -0.18 -0.64–0.28 -54 36*
Third Tertile
FRSþCACS 0.50* 0.17–0.82 17 33*
FRSþCACSþCCTA stenosis 0.62* 0.32–0.92 44* 18* 0.75* 0.46–1.04 50* 25*
FRS, Framingham 10-year risk score; cNRI, category-free net reclassification index; CACS, coronary artery calcium score; CCTA, coronary computed tomography angiography.
*P< 0.05.
................................................................................
....................................................................................................................................................................................................................
Table 3 Discriminatory value of coronary computed tomography angiography for predicting major adverse
cardiovascular events
Model C-statistic 95% CI P-value
Versus FRS model Versus FRS1CACS
Overall
FRS 0.63 0.55–0.71
FRSþCACS 0.71 0.64–0.78 0.022
FRSþCACSþCCTA stenosis 0.72 0.65–0.80 0.015 0.333
First tertile
FRS 0.53 0.31–0.74
FRSþCACS 0.53 0.31–0.74 0.990
FRSþCACSþCCTA stenosis 0.56 0.34–0.78 0.542 0.424
Second tertile
FRS 0.60 0.42–0.78
FRSþCACS 0.65 0.48–0.83 0.370
FRSþCACSþCCTA stenosis 0.60 0.42–0.78 0.978 0.058
Third tertile
FRS 0.58 0.47–0.68
FRSþCACS 0.70 0.63–0.77 0.031
FRSþCACSþCCTA stenosis 0.75 0.68–0.83 0.004 0.015
FRS, Framingham 10-year risk score; CACS, coronary artery calcium score; CCTA, coronary computed tomography angiography.
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Table 5 MACE risk reclassification comparing CACS and CCTA categories across FRS group in third age tertile
Third age tertile Reclassification accounting for CAD severity by CCTA
CACS category No CAD Non-obstructive
CAD
Obstructive
CAD—single vessel
Obstructive
CAD—multi vessel
Total number
Overall
Participants with events
0–10 3 5 2 0 10
10–100 0 3 2 0 5
101–400 0 1 3 3 7
>400 0 2 6 6 14
Total number 3 11 13 9 36
Participants without events
0–10 303 123 19 11 456
10–100 22 176 21 9 228
101–400 10 123 42 18 193
>400 4 59 39 50 152
Total number 339 481 121 88 1029
cNRI 51.2%, P= 0.001
FRS < 10%
Participants with events
0–10 0 0 0 0 0
10–100 0 0 0 0 0
101–400 0 1 2 0 3
>400 0 1 1 3 5
Total number 0 2 3 3 8
Participants without events
0–10 138 32 4 3 177
10–100 6 55 4 2 67
101–400 3 28 15 3 49
>400 2 11 7 8 28
Total number 149 126 30 16 321
cNRI -5.2%, P= 0.558
FRS 10–20%
Participants with events
0–10 3 2 1 0 6
10–100 0 2 1 0 3
101–400 0 0 1 2 3
>400 0 0 3 0 3
Total number 3 4 6 2 15
Participants without events
0–10 124 51 4 3 182
10–100 12 73 7 2 94
101–400 5 58 10 7 80
>400 1 20 13 13 47
Total number 142 202 34 25 403
cNRI 45.2%, P= 0.043
FRS >20%
Participants with events
0–10 0 3 1 0 4
10–100 0 1 1 0 2
101–400 0 0 0 1 1
>400 0 1 2 3 6
Total number 0 5 4 4 13
Continued
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value of CCTA beyond CACS and cardiac risk factors differs as a
function of age. In the current study, CCTA appeared to offer add-
itional prognostic benefit for risk stratification beyond traditional risk
factors as well as CACS in the uppermost tertile, representative of
older adults. To our knowledge, this is first study to assess the added
predictive value of CCTA in an asymptomatic population stratified by
age.
CAD risk prediction strategies often rely on the risk burden of
CAD. To this end, although CACS has been shown to provide risk
prediction beyond traditional risk factor scoring algorithms,22,23 prior
evidence has reported that the prognostic benefit of screening for
CACS often differs according to risk burden depending on the study
population.24,25 Compared with CACS, a widely used risk prediction
tool in asymptomatic individuals, CCTA is capable of further detect-
ing coronary plaque burden related to the location, severity, as well
as plaque characteristics. Recently, our group reported another sub-
group study from the CONFIRM registry, showing CCTA provided
incremental benefit towards predicting adverse cardiovascular events
in patients whose CACS was >100—indicative of more than moder-
ate CAD risk.12 When compared with the aforementioned study,
similar results were observed in the current investigation—the inci-
dence of MACE was very low in patients with low CVD risk (e.g.
CAC < 100 or low FRS) and CCTA did not improve reclassification
over CACS in patients with low FRS, even in the third age tertile
group. However, the current study suggested that age, as baseline
demographical information, might be considered when making a per-
sonalized decision for cardiovascular risk assessment at the time of
evaluation. Aging reflects a non-modifiable factor that further pro-
vokes the development of atherosclerosis and progression of its
components, the latter of which have previously been shown to in-
crease in tandem with advancing age.26 Further still, the present ob-
servations have demonstrated that more than one-third of patients in
the uppermost tertile of age presented with a CACS more than 100.
In light of this, our findings support the contention that CCTA might
serve a useful role as an effective screening tool in patients con-
sidered to be at moderate-to-high-risk, such as those with high
CACS or those representative of an elderly population. Therefore,
when we assess the CVD risk in asymptomatic population in clinical
practice, we may need to pay special attention for CVD risk screen-
ing strategy in elderly patients rather than younger patients. CCTA
can be a useful additive screening imaging tool over conventional risk
scoring system as well as CACS.
In recent past, several studies emphasized the importance of
CCTA for reclassifying asymptomatic individuals, particularly the cor-
rect reclassification of non-events. From one of the sub-studies from
the CONFIRM registry comprised of 3217 asymptomatic patients
stratified by CACS, CCTA improved reclassification, specifically in
patients presenting with high CACS.12 That is, CCTA reclassified pa-
tients with high CACS, wherein the results indicated correct reclassi-
fication primarily in those without an event (e.g. NRI = 0.55 non-
events correctly reclassified vs. 0.07 events correctly reclassified).
Likewise, Dedic et al.19 reported the prognostic value of CCTA in pa-
tients with at least one CAD risk factor but without cardiac symp-
toms. Notably, the latter study found CCTA correctly reclassified
only individuals without an event (e.g. NRI = 0.32 non-events cor-
rectly reclassified vs. 0.02 events correctly reclassified). The current
findings substantively extend upon these prior findings whereby
CCTA demonstrated correct reclassification not only among individ-
uals without an event but also among those who experienced an
event. Indeed, although it is well known that CACS > 400 is indicative
of high risk for future adverse outcomes, even non-obstructive CAD,
among patients with CACS > 400 most patients with events have ob-
structive CAD. Only two (3%) patients with no or non-obstructive
CAD experienced MACE in current study. In lieu of this, CCTA may
potentially afford correct reclassification of events as well as non-
events, at least in older asymptomatic individuals. This is perhaps an
important observation, given that approximately half of the US popu-
lation aged >65 years are considered statin eligible under the
American College of Cardiology/American Heart Association 2013
guidelines.27
The present study was not free from limitations. Although the
CONFIRM registry was prospective in nature, we cannot discount
the possibility of selection and follow-up bias as well as the potential
for unmeasured confounding factors that might have influenced the
clinical endpoints of this study. We included all-cause mortality in the
composite endpoint. As information regarding cause-specific mortal-
ity was unavailable in the CONFIRM registry, the proportion of
deaths by cardiovascular events is unknown in the current study. In
addition, the acquisition of information regarding downstream
pharmacological and/or interventional management after CCTA was
....................................... ....................................................................................................................................................................
....................................................................................................................................................................................................................
Table 5 Continued
Third age tertile Reclassification accounting for CAD severity by CCTA
CACS category No CAD Non-obstructive
CAD
Obstructive
CAD—single vessel
Obstructive
CAD—multi vessel
Total number
Participants without events
0–10 41 40 11 5 97
10–100 4 48 10 5 67
101–400 2 37 17 8 64
>400 1 28 19 29 77
Total number 48 153 57 47 305
cNRI 67.7%, P= 0.009
MACE, major adverse cardiovascular event; FRS, Framingham 10-year risk score; cNRI, category-free net reclassification index; CACS, coronary artery calcium score; CCTA,
coronary computed tomography angiography.
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unavailable. Therefore, the potential impact of CCTA result for treat-
ment choices and downstream events remains unknown. It also bears
mentioning that the follow-up duration was relatively short, and the
rate of events were particularly low in the first and second age ter-
tiles, which might offer some explanation to the suboptimal prognos-
tic value of CCTA when added to conventional risk factors as well as
CACS in those groups. The current study utilized the FRS for the
purpose of traditional risk stratification based on 10-year risk predic-
tion. A pressing limitation when employing this approach is the sub-
stantial disparity related to the duration of risk prediction, particularly
when 10-year FRS is applied to the present study’s 26-month median
follow-up duration. As such, any long-term predictive value of the
current study’s CCTA findings should be interpreted with caution.
Forthcoming studies with a lengthier follow-up duration are required
to determine whether CCTA improves risk prediction beyond trad-
itional approaches in asymptomatic populations.
Conclusion
In this study, CCTA demonstrated improved risk prediction and re-
classification above and beyond FRS and CACS among asymptomatic
older adults. CCTA may be considered useful for extending the pre-
dictive utility beyond currently available cardiac risk factors in the
elderly.
Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
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